<div id="readability-page-1"><p>SummerHaven Investment Management LLC bought a new stake in  Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,200 shares of the company's stock, valued at approximately $1,018,000. SummerHaven Investment Management LLC owned about 0.08% of Amphastar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li></ul><p>Other large investors have also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of  Amphastar Pharmaceuticals by 5.2% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company's stock worth $217,000 after purchasing an additional 465 shares during the last quarter.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of  Amphastar Pharmaceuticals by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company's stock valued at $652,000 after buying an additional 613 shares in the last quarter.  Global Retirement Partners LLC increased its holdings in  Amphastar Pharmaceuticals by 219.0% during the third quarter. Global Retirement Partners LLC now owns 1,024 shares of the company's stock worth $27,000 after buying an additional 703 shares during the last quarter.  Farther Finance Advisors LLC increased its holdings in  Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company's stock worth $25,000 after buying an additional 737 shares during the last quarter.  Finally, GAMMA Investing LLC raised its position in  Amphastar Pharmaceuticals by 62.2% during the second quarter. GAMMA Investing LLC now owns 2,162 shares of the company's stock worth $50,000 after acquiring an additional 829 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds. </p><h2>Amphastar Pharmaceuticals Stock Down 1.3%</h2><p>Amphastar Pharmaceuticals stock opened at $26.25 on Wednesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $37.38. The stock has a market cap of $1.21 billion, a P/E ratio of 11.62, a P/E/G ratio of 4.71 and a beta of 0.89. The company's 50-day moving average price is $26.69 and its two-hundred day moving average price is $26.16. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78. </p><ul><li>Promising Small Biotech Amphastar Sees Actionable Pullback </li></ul><p>Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.10. The company had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. As a group, analysts expect that  Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year. </p><h2>Insider Buying and Selling</h2><p>In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 16,679 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $26.49, for a total transaction of $441,826.71. Following the transaction, the director owned 75,531 shares in the company, valued at $2,000,816.19. This represents a 18.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the sale, the director owned 35,183 shares of the company's stock, valued at approximately $953,459.30. The trade was a 10.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 35,308 shares of company stock valued at $931,637. 27.10% of the stock is owned by company insiders. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research analysts have recently commented on AMPH shares. Barclays assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an &#34;equal weight&#34; rating and a $30.00 price objective for the company. Zacks Research cut Amphastar Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 14th. Needham &amp; Company LLC dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings  reaffirmed a &#34;hold (c-)&#34; rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and six have issued  a Hold rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals  has a consensus rating of &#34;Hold&#34; and an average price target of $31.00.</p><p><b>Get Our Latest Analysis on Amphastar Pharmaceuticals</b></p><h2>Amphastar Pharmaceuticals Profile</h2> (Free Report)<p>Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.  </p><p>Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.</p><h2>Read More</h2><ul><li>Five stocks we like better than Amphastar Pharmaceuticals</li><li>America's Next Power Move Starts Underground</li><li>Your Signature Is Missing – Act Before It’s Too Late</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li><li>Nvidia’s 3 Secret Partners</li></ul><p><strong>Want to see what other hedge funds are holding AMPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMPH

<p>SummerHaven Investment Management LLC acquired a $1.02 million stake in Amphastar Pharmaceuticals, purchasing 38,200 shares during Q3. Other institutional investors also increased their holdings. Amphastar's stock is currently down 1.3%, trading at $26.25, with a market cap of $1.21 billion. The company reported earnings of $0.93 per share, exceeding estimates. Recent insider sales have occurred, with directors reducing their stakes. Analysts have mixed ratings on the stock, with Barclays giving it an "equal weight" rating and a $30 price target.</p>

SummerHaven Investment Management LLC Takes $1.02 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH